안구건조증에서 히알우론산 단독치료와 사이클로스포린 A의 병합치료가 눈물막에 미치는 효과
Effect of Sodium Hyaluronate and Cyclosporine A on Tear Film in Dry Eye Syndrome
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
목적: 안구 건조증으로 진단받은 환자에서 0.1% 히알우론산나트륨 단독치료와 0.05% 사이클로스포린 병합치료가 눈물막에 미치는 효과를 비교하고자 한다. 대상과 방법: 안구 건조증을 진단받고 안과적 수술력이 없는 환자를 대상으로 0.1% 히알우론산나트륨만을 점안한 군(Group 1, 46안)과0.05% 사이클로스포린을 함께 점안한 군(Group 2, 54안)에서 안구 건조 증상에 대한 설문조사, 쉬르머검사, 눈물막파괴검사 및 눈물액 삼투압 검사를 치료 전과 치료 후 1, 2, 3개월 및 6개월째 분석하여 비교하였다. 결과: 두 군에서 설문조사 및 쉬르머검사는 각각 2개월, 1개월째에 유의한 호전을 보였고, 눈물막파괴검사는 Group 1에서는 3개월,Group 2에서는 1개월째에 호전 소견을 보였다. 눈물액 삼투압 검사는 두 군 모두 1개월째 호전을 보였으나 Group 2에서만 6개월까지지속적인 삼투압의 감소를 보였다. Group 2에서 눈물막파괴검사 및 쉬르머검사의 더 큰 호전이 있음을 확인할 수 있었다. 결론: 0.1% 히알우론산나트륨과 0.05% 사이클로스포린의 병합 사용은 안구 건조증의 개선에 더 효과적이라 생각한다.
Abstract
Purpose: To evaluate the efficacy of topical 0.1% hyaluronate (HA) and 0.05% cyclosporine A on tear film parameters in dry eye syndrome patients. Methods: Patients who were diagnosed with dry eye syndrome were treated with 0.1% HA only (Group 1, 46 eyes) or 0.1%HA combined with cyclosporine A (Group 2, 54 eyes). Ocular surface disease index (OSDI), tear film break-up time (BUT),Schirmer’s test, and tear osmolarity were evaluated before treatment and at 1, 2, 3, and 6 months after treatment. Results: OSDI was significantly improved at 2 months after treatment and Schirmer’s test results significantly improved at 1 month after treatment in both groups. The BUT was significantly improved 3 months after treatment in Group 1 and at 1month after treatment in Group 2. Tear osmolarity significantly improved at 1 month after treatment in both groups, but continuously improved up to 6 months after treatment only in Group 2. The BUT and Schirmer’s test showed greater improvements in Group 2 than in Group 1. Conclusions: Combined treatment of topical 0.1% HA and 0.05% cyclosporine A may be more effective for improving dry eye syndrome.
참고문헌 (31)
- 변용수, "안구건조증 환자에서 사이클로스포린 0.05퍼센트 점안액의 임상효과", 대한안과학회지, 49(10), pp.1583~1588 (2008), 대한안과학회
- Pflugfelder SC, "Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation", Cornea, 17, pp.38~56 (1998)
- Lemp MA, "The definition and classification of dry eye disease: report of the Definition and Classification. Subcommittee of the International Dry Eye Work Shop (2007)", Ocul Surf, 5, pp.75~92 (2007)
- Pflugfelder SC, "The diagnosis and management of dry eye: a twenty-five-year review", Cornea, 19, pp.644~649 (2000)
- Stern ME, "The pathology of dry eye: the interaction between the ocular surface and lacrimal glands", Cornea, 17, pp.584~589 (1998)
- Stern ME, "The role of the lacrimal functional unit in the pathophysiology of dry eye", Exp Eye Res, 78, pp.409~416 (2004)
- Smith VA, "Tear film MMP accumulation and corneal disease", Br J Ophthalmol, 85, pp.147~153 (2001)
- Solomon A, "Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease", Invest Ophthalmol Vis Sci, 42, pp.2283~2292 (2001)
- Argüeso P, "Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome", Invest Ophthalmol Vis Sci, 43, pp.1004~1011 (2002)
- Kunert KS, "Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine", Arch Ophthalmol, 120, pp.330~337 (2002)
- Hom MM, "Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients", Eye Contact Lens, 32, pp.109~111 (2006)
- Liu H, "A link between tear instability and hyperosmolarity in dry eye", Invest Ophthalmol Vis Sci, 50, pp.3671~3679 (2009)
- O’Brien PD, "Dry eye: diagnosis and current treatment strategies", Curr Allergy Asthma Rep, 4, pp.314~319 (2004)
- Stern ME, "Inflammation in dry eye", Ocul Surf, 2, pp.124~130 (2004)
- Pflugfelder SC, "Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca", Curr Eye Res, 19, pp.201~211 (1999)
- Stern ME, "Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye", Invest Ophthalmol Vis Sci, 43, pp.2609~2614 (2002)
- Fei WL, "Dry eye in graft-versus-host disease", Zhonghua Yan Ke Za Zhi, 39, pp.686~690 (2003)
- Ogawa Y, "Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation", Cornea, 22, pp.S19~S27 (2003)
- Ogawa Y, "Dry eye after haematopoietic stem cell transplantation", Br J Ophthalmol, 83, pp.1125~1130 (1999)
- 이종수, "경도의 안구 건조증에서 레스타시스®의 임상 효과", 대한안과학회지, 50(10), pp.1489~1494 (2009), 대한안과학회
- Borel JF, "In vivo pharmacological effects of ciclosporin and some analogues", Adv Pharmacol, 35, pp.115~246 (1996)
- Laibovitz RA, "Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca", Cornea, 12, pp.315~323 (1993)
- Power WJ, "Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjöngren’s syndrome", Cornea, 12, pp.507~511 (1993)
- Vanley GT, "Interpretation of tear film breakup", Arch Ophthalmol, 95, pp.445~448 (1977)
- Nichols KK, "The repeatability of clinical measurements of dry eye", Cornea, 23, pp.272~285 (2004)
- Nelson JD, "Tear film osmolality determination: an evaluation of potential errors in measurement", Curr Eye Res, 5, pp.677~681 (1986)
- White KM, "Human basic tear fluid osmolality. I. Importance of sample collection strategy", Acta Ophthalmol (Copenh), 71, pp.524~529 (1993)
- Gilbard JP, "Osmolarity of tear microvolumes in keratoconjunctivitis sicca", Arch Ophthalmol, 96, pp.677~681 (1978)
- Tomlinson A, "Tear film osmolarity: determination of a referent for dry eye diagnosis", Invest Ophthalmol Vis Sci, 47, pp.4309~4315 (2006)
- Wilson SE, "Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment", Ophthalmology, 114, pp.76~79 (2007)
- Barber LD, "Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years", Ophthalmology, 112, pp.1790~1794 (2005)